CKPTのニュース
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference 2022/05/19 12:30:00 GlobeNewswire
WALTHAM, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference, on Wednesday, May 25, 2022, at 3:00 p.m. ET. Checkpoint management will also participate in one-on-one meetings during the conference.
CKPT stock gains on key regulatory milestone in Europe (NASDAQ:CKPT) 2022/05/13 15:59:01 Seeking Alpha
The shares of clinical-stage biotech Checkpoint Therapeutics (CKPT) are trading sharply higher on Friday as H.C
Checkpoint Therapeutics GAAP EPS of -$0.20 2022/05/12 20:50:08 Seeking Alpha
Checkpoint Therapeutics press release (CKPT): Q1 GAAP EPS of -$0.20.As of March 31, 2022, Checkpoint’s cash and cash equivalents totaled $41.5 million, compared to $54.7 million…
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights 2022/05/12 20:30:00 GlobeNewswire
Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expected in 2022 Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expected in 2022
Checkpoint: Potential Upside Based On Marketing Application (NASDAQ:CKPT) 2022/04/18 18:15:52 Seeking Alpha
Checkpoint is a speculative biotech play to look into, because the company remains heavily undervalued based on recent progress. See more on CKPT stock here.
Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities 2022/04/04 12:15:00 GlobeNewswire
WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that members of Checkpoint’s management team will participate in the two-day Fortress Biotech (“Fortress”) Virtual R&D Summit taking place on Tuesday, April 5, 2022 and Wednesday, April 6, 2022. The Summit will be hosted by the B. Riley Securities’ Healthcare Equity Research team and will feature multiple programs from Fortress’ diversified pipeline.
Checkpoint Therapeutics: Q4 Earnings Insights 2022/03/28 12:08:09 Benzinga
Checkpoint Therapeutics (NASDAQ: CKPT ) reported its Q4 earnings results on Monday, March 28, 2022 at 07:30 AM. Here''s what investors need to know about the announcement. Earnings Checkpoint Therapeutics missed estimated earnings by 160.0%, reporting an EPS of … Full story available on Benzinga.com
Checkpoint Therapeutics GAAP EPS of -$0.75 misses by $0.24, revenue of $0.27M misses by $0.09M 2022/03/28 12:03:39 Seeking Alpha
Checkpoint Therapeutics press release (CKPT): FY GAAP EPS of -$0.75 misses by $0.24.Revenue of $0.27M (-74.8% Y/Y) misses by $0.09M.Shares +3.93% PM.
Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights 2022/03/28 11:30:00 GlobeNewswire
WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2021 and recent corporate highlights.
Analysts Predict A Surge In Checkpoint Therapeutics Inc. (NASDAQ: CKPT)? 2022/03/11 14:30:00 Stocks Register
Checkpoint Therapeutics Inc. (NASDAQ:CKPT) shares, rose in value on Thursday, 03/10/22, with the stock price up by 13.77% to the previous day’s close as strong demand from buyers drove the stock to $1.90. Actively observing the price movement in the last trading, the stock closed the session at $1.67, falling within a range of $1.61 … Analysts Predict A Surge In Checkpoint Therapeutics Inc. (NASDAQ: CKPT)? Read More »
Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference 2021/09/22 12:30:00 Intrado Digital Media
WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat hosted by Jennifer Kim, Vice President, Equity Research, at the 2021 Cantor Virtual Global Healthcare Conference, taking place on Monday, September 27, 2021, at 9:20 a.m. ET. Checkpoint management will also participate in one-on-one meetings during the conference. A live webcast of the fireside chat will be available on the Events page, located within the Investors section of Checkpoints website, https://ir.checkpointtx.com/event-calendar/default.aspx , for approximately 30 days following the meeting.
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences 2021/09/09 12:30:00 Intrado Digital Media
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences. Details are as follows: